Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and

Indication
Neovascular Age-related Macular Degeneration

Other upcoming events for OCUL

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, 3-Arm Parallel Group Study to Evaluate the Effica
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and
Phase 3 ReadoutPhase 3 Topline: A Phase 3b, Multicenter, Open-Label, Extension Study to Evaluate Long-Term Safety of Intravitreal OT
Patent ExpiryPatent/Exclusivity Expiry: DEXTENZA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and — OCUL Phase 3 Readout | BioSniper